Aitia latest strategic drug discovery collaboration with UCB, focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease. The collaboration will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing new therapies discovery for Huntington’s disease patients.
Read Pharmaceutical Technology full article here.
Picture Credit: Furiosa-L / Pixabay